The EMA at 20: A quality model that deserves to be replicated
This article was originally published in Scrip
Executive Summary
Despite initial industry misgivings, the European Medicines Agency has been a huge success, and initiatives like adaptive pathways and greater patient involvement show it is not resting on its laurels. But more could be done in areas such as pharmacovigilance, priority reviews and co-ordination among the agency's committees, say EFPIA's Richard Bergström and Pär Tellner.